FDA grants priority review status to Gilead's hepatitis C drug

[riky]

FDA grants priority review status to Gilead's hepatitis C drug

(Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir. The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies. The FDA set a review date of December 8 for the drug, Gilead said. Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue. ...

Source: You are not allowed to view links. Register or Login